Compare · FRMM vs NVO
FRMM vs NVO
Side-by-side comparison of Forum Markets Incorporated (FRMM) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both FRMM and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $191.15B, about 2376.8x FRMM ($80.4M).
- NVO has been more active in the news (8 items in the past 4 weeks vs 2 for FRMM).
- NVO has more recent analyst coverage (25 ratings vs 1 for FRMM).
- Company
- Forum Markets Incorporated
- Novo Nordisk A/S
- Price
- -
- -
- Market cap
- $80.4M
- $191.15B
- 1M return
- -
- -7.76%
- 1Y return
- -
- -45.65%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2017
- News (4w)
- 2
- 8
- Recent ratings
- 1
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest FRMM
- Forum Announces Initiation of Analyst Coverage by Sidoti & Company with $10.00 Price Target
- Forum to Present at Benchmark's Digital Assets Summit on May 27
- Forum Markets Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Forum Reports First Quarter 2026 Financial Results
- New insider Lomashuk Konstantin claimed ownership of 1,487,389 shares (SEC Form 3)
- Forum Announces Initiation of Analyst Coverage by Clear Street
- Forum Announces First Quarter 2026 Earnings Release Date and Webcast Details
- Forum Markets Incorporated filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- FORUM PROVIDES UPDATE ON SHARE REPURCHASE PROGRAM
- Forum Markets Incorporated filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care